392 related articles for article (PubMed ID: 23024113)
1. 131I-MIBG followed by consolidation with busulfan, melphalan and autologous stem cell transplantation for refractory neuroblastoma.
French S; DuBois SG; Horn B; Granger M; Hawkins R; Pass A; Plummer E; Matthay K
Pediatr Blood Cancer; 2013 May; 60(5):879-84. PubMed ID: 23024113
[TBL] [Abstract][Full Text] [Related]
2. Phase I dose escalation of iodine-131-metaiodobenzylguanidine with myeloablative chemotherapy and autologous stem-cell transplantation in refractory neuroblastoma: a new approaches to Neuroblastoma Therapy Consortium Study.
Matthay KK; Tan JC; Villablanca JG; Yanik GA; Veatch J; Franc B; Twomey E; Horn B; Reynolds CP; Groshen S; Seeger RC; Maris JM
J Clin Oncol; 2006 Jan; 24(3):500-6. PubMed ID: 16421427
[TBL] [Abstract][Full Text] [Related]
3. Feasibility of Busulfan Melphalan and Stem Cell Rescue After 131I-MIBG and Topotecan Therapy for Refractory or Relapsed Metastatic Neuroblastoma: The French Experience.
Ferry I; Kolesnikov-Gauthier H; Oudoux A; Cougnenc O; Schleiermacher G; Michon J; Bogart E; Chastagner P; Proust S; Valteau-Couanet D; Defachelles AS
J Pediatr Hematol Oncol; 2018 Aug; 40(6):426-432. PubMed ID: 29642099
[TBL] [Abstract][Full Text] [Related]
4. Pilot study of iodine-131-metaiodobenzylguanidine in combination with myeloablative chemotherapy and autologous stem-cell support for the treatment of neuroblastoma.
Yanik GA; Levine JE; Matthay KK; Sisson JC; Shulkin BL; Shapiro B; Hubers D; Spalding S; Braun T; Ferrara JL; Hutchinson RJ
J Clin Oncol; 2002 Apr; 20(8):2142-9. PubMed ID: 11956276
[TBL] [Abstract][Full Text] [Related]
5. Phase II study on the effect of disease sites, age, and prior therapy on response to iodine-131-metaiodobenzylguanidine therapy in refractory neuroblastoma.
Matthay KK; Yanik G; Messina J; Quach A; Huberty J; Cheng SC; Veatch J; Goldsby R; Brophy P; Kersun LS; Hawkins RA; Maris JM
J Clin Oncol; 2007 Mar; 25(9):1054-60. PubMed ID: 17369569
[TBL] [Abstract][Full Text] [Related]
6. 131I-metaiodobenzylguanidine with intensive chemotherapy and autologous stem cell transplantation for high-risk neuroblastoma. A new approaches to neuroblastoma therapy (NANT) phase II study.
Yanik GA; Villablanca JG; Maris JM; Weiss B; Groshen S; Marachelian A; Park JR; Tsao-Wei D; Hawkins R; Shulkin BL; Jackson H; Goodarzian F; Shimada H; Courtier J; Hutchinson R; Haas-Koga D; Hasenauer CB; Czarnecki S; Katzenstein HM; Matthay KK
Biol Blood Marrow Transplant; 2015 Apr; 21(4):673-81. PubMed ID: 25639769
[TBL] [Abstract][Full Text] [Related]
7. Myeloablative Busulfan/Melphalan Consolidation following Induction Chemotherapy for Patients with Newly Diagnosed High-Risk Neuroblastoma: Children's Oncology Group Trial ANBL12P1.
Granger MM; Naranjo A; Bagatell R; DuBois SG; McCune JS; Tenney SC; Weiss BD; Mosse YP; Asgharzadeh S; Grupp SA; Hogarty MD; Gastier-Foster JM; Mills D; Shulkin BL; Parisi MT; London WB; Han-Chang J; Panoff J; von Allmen D; Jarzembowski JA; Park JR; Yanik GA
Transplant Cell Ther; 2021 Jun; 27(6):490.e1-490.e8. PubMed ID: 33823167
[TBL] [Abstract][Full Text] [Related]
8. Feasibility and effectiveness of treatment strategy of tandem high-dose chemotherapy and autologous stem cell transplantation in combination with
Suh JK; Koh KN; Min SY; Kim YS; Kim H; Im HJ; Namgoong JM; Kim DY; Ahn SD; Lee JJ; Seo JJ
Pediatr Transplant; 2020 Mar; 24(2):e13658. PubMed ID: 31960542
[TBL] [Abstract][Full Text] [Related]
9. Iodine-131-metaiodobenzylguanidine as initial induction therapy in stage 4 neuroblastoma patients over 1 year of age.
de Kraker J; Hoefnagel KA; Verschuur AC; van Eck B; van Santen HM; Caron HN
Eur J Cancer; 2008 Mar; 44(4):551-6. PubMed ID: 18267358
[TBL] [Abstract][Full Text] [Related]
10. High-dose iodine-131-metaiodobenzylguanidine with haploidentical stem cell transplantation and posttransplant immunotherapy in children with relapsed/refractory neuroblastoma.
Toporski J; Garkavij M; Tennvall J; Ora I; Gleisner KS; Dykes JH; Lenhoff S; Juliusson G; Scheding S; Turkiewicz D; Békássy AN
Biol Blood Marrow Transplant; 2009 Sep; 15(9):1077-85. PubMed ID: 19660720
[TBL] [Abstract][Full Text] [Related]
11. Long-term results of the combination of the N7 induction chemotherapy and the busulfan-melphalan high dose chemotherapy.
Valteau-Couanet D; Le Deley MC; Bergeron C; Ducassou S; Michon J; Rubie H; Le Teuff G; Coze C; Plantaz D; Sirvent N; Bouzy J; Chastagner P; Hartmann O
Pediatr Blood Cancer; 2014 Jun; 61(6):977-81. PubMed ID: 23970413
[TBL] [Abstract][Full Text] [Related]
12. Dose escalation study of no-carrier-added 131I-metaiodobenzylguanidine for relapsed or refractory neuroblastoma: new approaches to neuroblastoma therapy consortium trial.
Matthay KK; Weiss B; Villablanca JG; Maris JM; Yanik GA; Dubois SG; Stubbs J; Groshen S; Tsao-Wei D; Hawkins R; Jackson H; Goodarzian F; Daldrup-Link H; Panigrahy A; Towbin A; Shimada H; Barrett J; Lafrance N; Babich J
J Nucl Med; 2012 Jul; 53(7):1155-63. PubMed ID: 22700000
[TBL] [Abstract][Full Text] [Related]
13. Phase I dose escalation of 131I-metaiodobenzylguanidine with autologous bone marrow support in refractory neuroblastoma.
Matthay KK; DeSantes K; Hasegawa B; Huberty J; Hattner RS; Ablin A; Reynolds CP; Seeger RC; Weinberg VK; Price D
J Clin Oncol; 1998 Jan; 16(1):229-36. PubMed ID: 9440747
[TBL] [Abstract][Full Text] [Related]
14. Resource Utilization and Toxicities After Carboplatin/Etoposide/Melphalan and Busulfan/Melphalan for Autologous Stem Cell Rescue in High-Risk Neuroblastoma Using a National Administrative Database.
Desai AV; Seif AE; Li Y; Getz K; Fisher BT; Huang V; Mante A; Aplenc R; Bagatell R
Pediatr Blood Cancer; 2016 May; 63(5):901-7. PubMed ID: 26797923
[TBL] [Abstract][Full Text] [Related]
15. Feasibility, toxicity and response of upfront metaiodobenzylguanidine therapy therapy followed by German Pediatric Oncology Group Neuroblastoma 2004 protocol in newly diagnosed stage 4 neuroblastoma patients.
Kraal KC; Bleeker GM; van Eck-Smit BL; van Eijkelenburg NK; Berthold F; van Noesel MM; Caron HN; Tytgat GA
Eur J Cancer; 2017 May; 76():188-196. PubMed ID: 28329731
[TBL] [Abstract][Full Text] [Related]
16. Treatment of advanced neuroblastoma: feasibility and therapeutic potential of a novel approach combining 131-I-MIBG and multiple drug chemotherapy.
Mastrangelo S; Tornesello A; Diociaiuti L; Pession A; Prete A; Rufini V; Troncone L; Mastrangelo R
Br J Cancer; 2001 Feb; 84(4):460-4. PubMed ID: 11207038
[TBL] [Abstract][Full Text] [Related]
17. The potential role of pretransplant MIBG diagnostic scintigraphy in targeted administration of 131I-MIBG accompanied by ASCT for high-risk and relapsed neuroblastoma: a pilot study.
Hamidieh AA; Beiki D; Paragomi P; Fallahi B; Behfar M; Fard-Esfahani A; Hosseini AS; Shamshiri A; Eftekhari M; Ghavamzadeh A
Pediatr Transplant; 2014 Aug; 18(5):510-7. PubMed ID: 24814429
[TBL] [Abstract][Full Text] [Related]
18.
Giardino S; Piccardo A; Conte M; Puntoni M; Bertelli E; Sorrentino S; Montera M; Risso M; Caviglia I; Altrinetti V; Lanino E; Faraci M; Garaventa A
Pediatr Blood Cancer; 2021 Feb; 68(2):e28775. PubMed ID: 33099289
[TBL] [Abstract][Full Text] [Related]
19. Phase I study of high-dose busulfan, melphalan and thiotepa with autologous stem cell support in patients with refractory malignancies.
Weaver CH; Bensinger WI; Appelbaum FR; Lilleby K; Sandmaier B; Brunvand M; Rowley S; Petersdorf S; Rivkin S; Gooley T
Bone Marrow Transplant; 1994 Nov; 14(5):813-9. PubMed ID: 7889015
[TBL] [Abstract][Full Text] [Related]
20. High-dose busulfan and melphalan as conditioning regimen for autologous peripheral blood progenitor cell transplantation in high-risk neuroblastoma patients.
Molina B; Alonso L; Gonzalez-Vicent M; Andion M; Hernandez C; Lassaletta A; Cormenzana M; Lopez-Ibor B; Villa M; Molina J; Diaz MA
Pediatr Hematol Oncol; 2011 Mar; 28(2):115-23. PubMed ID: 21299340
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
